首页|精确放疗联合吉非替尼治疗老年局部晚期非小细胞肺癌的疗效

精确放疗联合吉非替尼治疗老年局部晚期非小细胞肺癌的疗效

扫码查看
目的 探讨精确放疗联合吉非替尼在治疗老年局部晚期非小细胞肺癌患者中的临床应用效果.方法 选取2014年12月~2016年1月山西省肿瘤医院收治的局部晚期非小细胞肺癌患者88例,随机数字表法均分为对照组和研究组(n=44),对照组给予单纯放疗,研究组则在精确放疗基础上给予吉非替尼口服治疗,临床干预3个月评价2组临床疗效,比较2组干预前后血清肿瘤标志物(CEA、CA125、CA242)水平的变化,观察并比较2组不良反应的发生情况.结果 研究组和对照组疾病控制率分别为90.91%和72.72%,差异有统计学意义(P<0.05);治疗后2组患者CEA、CA125与CA242水平均较治疗前明显降低(P<0.05),治疗后研究组降低程度比对照组更为显著(P<0.05);研究组和对照组不良反应发生率分别为34.14%和27.27%,进行秩和检验可知研究组VS对照组(Z=0.657,P=0.511),组间差异无统计学意义.结论 精确放疗联合吉非替尼在老年局部晚期NSCLC患者治疗中是一种安全的治疗手段,能够有效提高临床疗效,改善血清肿瘤标志物水平,值得临床应用推广.
Therapeutic effect of precise radiotherapy combined with gefitinib in the treatment of elderly patients with advanced non - small cell lung cancer
Objective To explore the clinical effect of precise radiotherapy combined with gefitinib in the treatment of elderly patients with locally advanced non -small cell lung cancer. Methods 88 cases with locally advanced non small cell lung cancer patients treated from December 2014 to January 2016 in Shanxi Cancer hospital were randomly divided into control group and study group (n=44) by random number table method, the control group received radiotherapy, the study group on precise radiotherapy given gefitinib oral treatment, clinical intervention for 3 months evaluation of clinical efficacy of the two groups, the levels of serum tumor markers (CEA, CA125, CA242) in the two groups were compared before and after the intervention, and the incidence of adverse drug reactions was observed and compared. Results The control rate of the study group and the control group were 90.91% and 72.72% respectively, the difference was statistically significant (P<0.05). After treatment, the levels of CEA, CA125 and CA242 in the two groups were significantly lower than those in the control group (P<0.05). The level of CEA, CA125 and CA242 in the study group was significantly lower than that in the control group (P<0.05), after treatment the study group decreased more significant than the control group (P<0.05). The study group and the control group had adverse adverse reaction rates were 34.14% and 27.27%, and rank sum test the research group VS control group (Z=0.657, P=0.511), there was no significant difference between the two groups. Conclusion Precise radiotherapy combined with gefitinib in the elderly patients with locally advanced NSCLC treatment is a safe treatment method, can effectively improve the clinical efficacy, improve the level of serum tumor markers, it is worthy of clinical application.

non small cell lung cancerelderlyradiotherapygefitinibcurative effectlocal advanced

李波

展开 >

山西省肿瘤医院,山西 太原 030013

非小细胞肺癌 老年 精确放疗 吉非替尼 疗效 局部晚期

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(9)
  • 5
  • 7